Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration.

Science Corp, a clinical-stage medical technology company led by Max Hodak and the team, has announced the European commercial launch of PRIMA, the first and only treatment shown in clinical trials to restore functional central vision to patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD), a leading cause of blindness.

PRIMA has received a CE (Conformité Européenne) mark under the European Union Medical Device Regulation from DEKRA, authorizing its commercial availability across 30 European countries.

PRIMA has become the first BCI device to receive CE marking for restoring detailed form vision, including the ability to read letters, numbers, and words. Country-specific reimbursement applications and clinical site activations are now underway across Europe, with the first commercial implant expected soon in Germany.

The milestone marks a major step forward for people affected by geographic atrophy associated with age-related macular degeneration (AMD), a condition that progressively destroys central vision needed for reading, face recognition, and independence. After decades without a viable treatment, PRIMA offers a potential path toward restoring functional vision.

In the United States, regulatory efforts with the FDA are ongoing. PRIMA has already received both Breakthrough Device and Humanitarian Use Device designations.

AMD-associated geographic atrophy affects more than five million people globally, representing one of the largest unmet needs in vision restoration.

A multi-center clinical trial published in the New England Journal of Medicine evaluated the PRIMA BCI implant system in 38 patients across 17 clinical sites in five countries. The study demonstrated significant improvements in functional vision, including:

• An average improvement of 25.5 letters (more than five lines) on the ETDRS letter chart.

• 84% of patients regained the ability to read letters, numbers, and words through restored central vision.

• 80% of patients achieved clinically meaningful prosthetic visual acuity improvements of at least logMAR 0.2 (equivalent to 10 ETDRS letters) at 12 months (p<0.001).

• The implant was successfully placed beneath the atrophic macula without reducing existing natural vision.

The PRIMA BCI system combines a novel subretinal photovoltaic implant with specialized glasses to restore functional vision. The glasses project near-infrared light onto the implant, which converts the signals into electrical stimulation for the retina. A built-in “zoom-in” feature helps patients magnify letters, while the ultra-thin implant design enables wireless and seamless integration.